STOCK TITAN

TARS (NASDAQ: TARS) insider sale notice; Bryan Wahl disposed of 8,209 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

TARS filed a Form 144 reporting proposed sale of 4,231 shares of Common Stock. The filing also records recent dispositions by Bryan Wahl of 4,084 shares on 03/17/2026 and 4,125 shares on 03/18/2026, with dollar entries of 283,489.63 and 283,427.93 respectively.

The notice lists a brokerage holder, Fidelity Brokerage Services LLC, and identifies a 03/18/2026 restricted stock vesting classified as Compensation. This Form 144 is a routine disclosure of intended resale under Rule 144 and related recent insider dispositions.

Positive

  • None.

Negative

  • None.

Insights

Routine Rule 144 resale notice and recent insider dispositions disclosed.

The filing lists a proposed resale of 4,231 shares and shows prior dispositions by Bryan Wahl of 4,084 and 4,125 shares on 03/17/2026 and 03/18/2026.

These entries appear procedural: ensure the resale meets Rule 144 holding-period and volume conditions and confirm whether the reported dollar figures reflect proceeds or cost basis; timing and cash‑flow treatment are not stated beyond the dates shown.

Insider activity is modest in scale and disclosed as compensation-related vesting and subsequent sales.

The schedule shows a restricted stock vesting on 03/18/2026 labeled Compensation and two near-dated dispositions by the same individual, Bryan Wahl, totaling 8,209 shares across the two noted sales dates.

Observe future filings for any pattern of systematic dispositions; these Form 144 notices document resale intentions rather than corporate action or change in control.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TARS Form 144 report show?

It reports a proposed resale of 4,231 common shares and recent insider dispositions totaling 8,209 shares. The filing lists sales on 03/17/2026 and 03/18/2026 and notes a restricted stock vesting classified as Compensation.

Who is named as the broker in the TARS Form 144?

The filing names Fidelity Brokerage Services LLC as the broker-dealer associated with the resale filing. The entry includes an address for the broker and a NASDAQ designation in the securities line.

How many shares did Bryan Wahl report selling in recent entries?

Bryan Wahl reported dispositions of 4,084 shares on 03/17/2026 and 4,125 shares on 03/18/2026. Dollar amounts shown are 283,489.63 and 283,427.93 alongside the share counts.

Does the Form 144 indicate why the shares vested?

Yes; the filing labels the 03/18/2026 vesting as Restricted Stock Vesting and classifies the source as Compensation. No further compensation plan details are provided in the excerpt.

Does this Form 144 confirm monetary proceeds to the issuer?

The filing shows dollar figures alongside certain sales entries but does not state proceeds to the issuer. Cash-flow treatment or recipient of funds is not detailed beyond the numeric entries.
Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

View TARS Stock Overview

TARS Rankings

TARS Latest News

TARS Latest SEC Filings

TARS Stock Data

2.73B
40.38M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
IRVINE